SCHEMBL29636637

SCHEMBL29636637

CN1CCC(N2CCC(c3cc(N)c4ccccc4n3)CC2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 3/20 0.51
NCF1 P14598 2/20 0.42
ACVR1 Q04771 2/20 0.42
HRH4 Q9H3N8 2/20 0.41
POLB P06746 2/20 0.41
ACHE P22303 1/20 0.40
TLR9 Q9NR96 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
ALDH1A1 P00352 1/20 0.39
HPGD P15428 1/20 0.39
HTT P42858 1/20 0.39
BMPR1B O00238 1/20 0.39
BMPR1A P36894 1/20 0.39
ACVR1B P36896 1/20 0.39
TGFBR1 P36897 1/20 0.39
GRIN2B Q13224 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29636853 0.85 NCF1 (0.42) HTR3ANCF1ACVR1HRH4POLB
SCHEMBL31677954 0.73 POLB (0.49) HTR3ANCF1POLBACHEALDH1A1
SCHEMBL30998387 0.73 HRH4 (0.50) HTR3ANCF1HRH4POLBACHE
Hydrochloric Acid SCHEMBL29862942 0.72 KMT2A (0.49) HTR3ANCF1HRH4POLBACHE
SCHEMBL31579478 0.71 HTR3A (0.56) HTR3ANCF1HRH4POLBALDH1A1
SCHEMBL29636762 0.71 NCF1 (0.38) HTR3ANCF1ACVR1POLBACHE
SCHEMBL30824486 0.68 HRH3 (0.53) HTR3AHRH4ALDH1A1MAPK1SMN1; SMN2
SCHEMBL4437035 0.68 HRH3 (0.53) HTR3AHRH4ALDH1A1MAPK1SMN1; SMN2
SCHEMBL5910851 0.68 HTR3A (1.00) HTR3ANCF1HRH4ALDH1A1KMT2A
SCHEMBL10127720 0.67 GRIN2B (0.48) TLR9TLR7ALDH1A1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4017492-A1 MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS Biohaven Therapeutics Ltd. (US) 2022-06-29 EP claimed